meningococcal A C Y and W-135 polysaccharide vaccine combined (Menomune A/C/Y/W-135)
- Dosing and uses of Menomune A/C/Y/W-135 (meningococcal A C Y W-135 polysaccharide vaccine combined)
- Menomune A/C/Y/W-135 (meningococcal A C Y W-135 polysaccharide vaccine combined) adverse (side) effects
- Warnings
- Pregnancy
- Pharmacology of Menomune A/C/Y/W-135 (meningococcal A C Y W-135 polysaccharide vaccine combined)
Dosing and uses of Menomune A/C/Y/W-135 (meningococcal A C Y W-135 polysaccharide vaccine combined)
Adult dosage forms and strengths
vaccine
- 0.5mL/vial
Meningococcal Vaccination
Indicated active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in persons aged 2 years or older
ACIP recommendations: Preferred vaccine for adults ≥56 yr who have not received MenACWY conjugate vaccine (Menactra, Menveo) previously and who require a single dose only (eg, travelers)
0.5 mL SC as a single dose
Up-to-date vaccination schedules available at https://www.cdc.gov/vaccines/schedules/hcp/index.htmL
Dosing Considerations
MenACWY conjugate vaccine (Menactra, Menveo) preferred for outbreak situations and high risk individuals
Administration
Preferably in deltoid region
Pediatric dosage forms and strengths
vaccine
- 0.5mL/vial
Immunization
Indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in persons aged 2 years or older
Although approved by the FDA for children ≥2 yr, ACIP pediatric vaccination guidelines do not include the polysaccharide vaccine (Menomune)
<2 years: Safety and efficacy not established
0.5 mL SC as a single dose
Up-to-date vaccination schedules available at https://www.cdc.gov/vaccines/schedules/hcp/index.htmL
Dosing Considerations
MenACWY conjugate vaccine (Menactra, Menveo) preferred for outbreak situations and high risk individuals
Administration
Preferable in deltoid region
Menomune A/C/Y/W-135 (meningococcal A C Y W-135 polysaccharide vaccine combined) adverse (side) effects
Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967
>10%
Anorexia
Arthralgia
Diarrhea
Fatigue
Headache
Induration
Malaise
Pain
Redness
Swelling
1-10%
Chills
Fever
Rash
Vomiting
Warnings
Contraindications
Hypersensitivity to any component, including dry natural rubber latex (present in vial stopper)
Cautions
A few cases of Guillain Barre syndrome reported following administration, causality unknown
Not indicated for N. meningitidis serogroup B
Patients with bleeding disorder
Immunosuppressed patients
Pregnancy and lactation
Pregnancy category: C
Lactation: use caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Menomune A/C/Y/W-135 (meningococcal A C Y W-135 polysaccharide vaccine combined)
Mechanism of action
Meningococcal serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein carrier
These products convey active immunity via stimulation of production of endogenously produced antibodies